• This  mee(ng  is  organised  and  paid  for  by  Janssen  

• Slide  content  has  been  reviewed  by  Janssen  to  ensure  compliance  with  the  ABPI  Code  of  Prac(ce  for  the  Pharmaceu(cal  Industry.    

• Speakers  may  express  personal  opinions  that  are  not  necessarily  shared  by  Janssen.  

   • Adverse  events  should  be  reported.  Repor(ng  forms  and  informa(on  can  be  found  at  www.mhra.gov.uk/yellowcard  Adverse  events  should  also  be  reported  to  Janssen-­‐Cilag  Ltd  on  01494  567447.  

• Prescribing  Informa(on  is  available  at  this  mee(ng.  

Janssen-­‐Cilag  Ltd,  50-­‐100  Holmers  Farm  Way,  Buckinghamshire,  HP12  4EG,  UK  

   ▼ Invokana®  (canagliflozin)  This  medicinal  product  is  subject  to  addi4onal  monitoring  and  it  is  therefore  important  to  report  any  suspect  adverse  reac4ons  related  to  this  medicinal  product.  

3+1%):&1',W%=OT<DXYVDGKHKDGGZH%[-7'%+0%=,'/-,-(+)W%\-2%RGHK%

j jijoihoi

jijoihoi

Up to 80% of diabetics will die of Cardiovascular disease

j jijoihoi

jijoihoi

N.B.  Medicine  no  longer  available  in  the  UK  

^^%

[-7'%+0%/,'/-,-(+)W%\-,6"%RGHZ%3+1%):&1',W%RRLMMGK%

3+1%):&1',W%=OT<DXYVDGKHKDGGZH%[-7'%+0%=,'/-,-(+)W%\-2%RGHK%